KR20070060420A - Composition for preventing and treating diabetes - Google Patents
Composition for preventing and treating diabetes Download PDFInfo
- Publication number
- KR20070060420A KR20070060420A KR1020050119784A KR20050119784A KR20070060420A KR 20070060420 A KR20070060420 A KR 20070060420A KR 1020050119784 A KR1020050119784 A KR 1020050119784A KR 20050119784 A KR20050119784 A KR 20050119784A KR 20070060420 A KR20070060420 A KR 20070060420A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- red ginseng
- chaga
- ginseng
- ruba
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title abstract description 7
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 114
- 239000000284 extract Substances 0.000 claims abstract description 111
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- 239000008280 blood Substances 0.000 claims abstract description 18
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 235000000346 sugar Nutrition 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 29
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 235000013376 functional food Nutrition 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 2
- 238000003809 water extraction Methods 0.000 claims 1
- 240000004371 Panax ginseng Species 0.000 abstract description 21
- 241000709400 Ruba Species 0.000 abstract description 9
- 241000414067 Inonotus obliquus Species 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000020710 ginseng extract Nutrition 0.000 description 5
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000123392 Hymenochaetaceae Species 0.000 description 1
- CSYGXJQNODZRQO-UHFFFAOYSA-N Inotodiol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CC(O)C12C)C4(C)CCC(O)C(C)(C)C4CC3 CSYGXJQNODZRQO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JUHFNIHWCGKLPH-UHFFFAOYSA-N Obliquol Natural products O1C(=O)C=CC2=C1C=C1OCC(C(=C)CO)OC1=C2 JUHFNIHWCGKLPH-UHFFFAOYSA-N 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000019194 Sorbus aucuparia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 101150069072 cdc25 gene Proteins 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 208000027407 head symptom Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- -1 lannosterol Chemical compound 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000006414 serbal de cazadores Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 홍미삼 추출물 또는 홍미삼과 차가버섯의 혼합 추출물을 함유하는, 당뇨병을 예방 및 치료하기 위한 약학 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition for preventing and treating diabetes mellitus, comprising a red ginseng extract or a mixed extract of red ginseng and chaga.
당뇨병은 체내의 불연소된 당이 소변을 통해 체외로 배출되는 질환으로, 당뇨병 환자는 혈당량이 매우 높으므로, 혈액의 점도가 증가하여 혈액 순환상태가 나빠지며, 이로 인하여 각 장기 및 세포로 혈액이 정상적으로 공급되지 못하여 세포 및 조직에 손상을 야기하기도 한다.Diabetes is a disease in which unburned sugars in the body are discharged out of the body through urine. Diabetes patients have a very high blood sugar level, which leads to an increase in the viscosity of the blood, resulting in poor blood circulation. Failure to supply normally can cause damage to cells and tissues.
현재 사용되고 있는 당뇨병의 치료 방법은 환자의 혈당량을 강하시키는 것이 주된 목적으로, 식이요법, 운동, 인슐린의 작용을 증가시키는 약물 및 외인성 인슐린의 투여 등이 포함된다.Currently used methods of treating diabetes lower the blood sugar level of the patient, and include diet, exercise, drugs that increase the action of insulin, and administration of exogenous insulin.
그러나, 식이요법 및 운동은 강한 인내심을 가지고 지속적, 반복적으로 수행되어야 하기 때문에 대중적인 효과를 보기 어렵고, 인슐린의 작용을 증가시키는 약물은 효과가 우수하기는 하나, 부작용을 초래할 수 있으며, 외인성 인슐린은 가격 이 매우 비싸며, 환자에게 고통스러운 투여 과정을 필요로 할 뿐만 아니라, 합병증 및 부작용이 발생할 수 있다.However, diet and exercise are difficult to achieve the popular effect because they have to be carried out continuously and repeatedly with strong patience, and drugs that increase the action of insulin are effective, but may cause side effects. The price is very expensive and not only requires a painful administration procedure for the patient, but also complications and side effects can occur.
따라서, 최근에는 이러한 문제점을 최소화하기 위해 천연물을 재료로 하는 항당뇨 기능성 식품 및 치료제 등의 개발이 활발히 진행되고 있다.Therefore, in recent years, development of anti-diabetic functional foods and therapeutic agents made of natural materials has been actively conducted to minimize such problems.
홍삼 (Panax ginseng ruba) 및 인삼 (Panax ginseng)은 항당뇨제로서 예로부터 민간에서 사용되어 왔으며, 현대 의학에서도 당뇨병에 대한 효능이 이미 확인되었다 (Sotantemi EA et al., Diabetes care 18(10):1373 (1995)). Red ginseng (Panax ginseng ruba) and ginseng (Panax ginseng) have been used in folk medicine as antidiabetics since ancient times, and efficacy in diabetes has already been confirmed in modern medicine (Sotantemi EA et al., Diabetes care 18 (10): 1373 (1995)).
예를 들면, 인삼으로부터 분리한 혈당강하 성분 (DPG3-2)을 이용한 동물실험을 통해 상기 성분이 인슐린 분비 촉진 기능을 가지고 있음을 확인하였으며 (기무라, 제3회 국제인삼심포지움, 1980), 당뇨병 환자에게 홍삼을 투여한 임상 실험 결과, 환자에 따라 혈당량이 저하되고 인슐린 치료환자에 있어서 인슐린 투여 감소가 가능했으며, 특히 자각 증상인 현기증, 어깨 결림, 흉부압박감, 갈증, 전신 권태감, 머리가 무거운 증상 등이 크게 개선되었다는 보고가 있다 (조순승 등, 고려인삼학회-고려인삼의 이해, 20 (1995)). 또한, 백삼, 홍삼, 화기삼의 내당능 실험 및 당뇨쥐 실험 모델에서의 혈당강하 효과를 측정한 결과 특히 홍삼에서 우수한 결과가 나왔으며, 인슐린 레벨도 증가시킨다는 논문이 발표된 바 있다 (Park KS et al, J. Ginseng Res. 27(2):56-61 (2003)). For example, animal experiments using hypoglycemic components (DPG3-2) isolated from ginseng confirmed that the components had a function of promoting insulin secretion (Kimura, 3rd International Ginseng Symposium, 1980), diabetics The results of clinical trials in which red ginseng was administered showed that blood sugar levels decreased and insulin administration was reduced in patients treated with insulin, especially subjective symptoms such as dizziness, stiff shoulder, chest compressions, thirst, general malaise, and heavy head symptoms. There is a report that this has been greatly improved (Jo Sun-seung et al., Korea Ginseng Society-Understanding Korean Ginseng, 20 (1995)). In addition, the results of measuring the hypoglycemic effect in the glucose tolerance test and diabetic rat model of white ginseng, red ginseng, and Hwagi ginseng showed excellent results, especially in red ginseng and increased insulin levels (Park KS et al, J. Ginseng Res. 27 (2): 56-61 (2003)).
이처럼 홍삼의 경우 다른 삼들에 비해 항당뇨 효과가 우수하나 효과를 나타낼 수 있을 만큼의 용량으로 제조 및 제공한다는 것은 가격적인 측면에서 비경제적이라는 문제점을 가지고 있다.As such, red ginseng has an excellent anti-diabetic effect compared to other ginsengs, but has a problem that it is uneconomical in terms of manufacturing and providing at a dose sufficient to exhibit the effect.
한편, 홍미삼은 홍삼으로는 사용하지 않는 미삼만을 사용하여 만들어지며, 홍삼의 약용부위로 인정된 바도 없다. 또한, 홍미삼은 홍삼에 비해 가격적인 측면에서 훨씬 경제적임에도 불구하고, 현재까지 인삼과 홍삼에 비해 많은 연구가 진행되지 않은 상황이다.On the other hand, red ginseng is made using only the red ginseng not used as red ginseng, has not been recognized as a medicinal part of red ginseng. In addition, although red ginseng is much more economical in terms of price than red ginseng, much research has not been carried out compared to ginseng and red ginseng.
한편, 차가버섯 (Inonotus obliquus)은 소나무 비닐버섯과 (Hymenochaetaceae)에 속하는 다년생의 담자균버섯으로 북위 45도 이상의 춥고 습한 북반구에 분포하며 자연 상태에서 성장하면 검은색의 균핵 덩어리가 되어 자작나무, 오리나무 마가목 등의 줄기나 그루터기에 자생하는 극내한성 버섯이다 (Kahlos K. Biotech. in Agri and Fores. 26:179-198 (1994)). 차가버섯의 성분으로는 천연색소인 멜라닌과 플라보노이드, 트리터펜, 오브리쿠올 (obliquol), 란노스테롤, 이노시톨, 아가산 (agaric acid), 폴리페놀, β-헤테로 글루칸, 리그닌 및 알칼로이드 등이 있으며, 무기질로는 Ca, Mg, Fe 및 Mn 등이 함유되어 있으며, 민간에서 혈압조절, 신체 저항력 증강, 종양발생억제 등에 사용되고 있을 뿐만 아니라 당뇨, 신경통, 신경쇠약 등 많은 질병의 치료를 위하여 이용되고 있다.On the other hand, chaga ( Inonotus obliquus ) is a perennial basidiomycete belonging to the genus Pine Vinyl Mushroom (Hymenochaetaceae), which is distributed in the cold and humid northern hemisphere above 45 degrees latitude. Extremely cold-tolerant mushrooms native to the stems and stumps of rowan (Kahlos K. Biotech. In Agri and Fores. 26: 179-198 (1994)). Chaga's ingredients include melanin, flavonoids, triterpenes, obliquol, lannosterol, inositol, agaric acid, polyphenols, β-heteroglucans, lignin and alkaloids. The furnace contains Ca, Mg, Fe, and Mn, and is used in the private sector for blood pressure control, body resistance enhancement, tumor suppression, and the like, and is used for the treatment of many diseases such as diabetes, neuralgia, and nervous breakdown.
차가버섯의 생리활성에 대한 연구로는 항종양 (Bultov PK et al., Tsaga ii ee letsebnoje primenie pirake Ⅳ. Stadii Leningrad 326 (1959); Shivrina AN, Chem Abstr. 66:17271-17279 (1967); Loviagina EV et al., Biobimija 27:794-800 (1962); 및 Kahlos K. et al., Acta Pharm Fenn 96:33-40 (1987)), 항돌연변이 (Saitoh et al., 道衛硏究報 第46集 (1996)), 항바이러스 (Kahlos K et al., Fitoterapia 57:4 (1996); 및 Ichmura T et al., Biosci. Biotechnol. Biochem. 62:575 (1998)), 및 항산화 (Cui Y et al., J. Ethnopharmacol. 96(1-2):79 (2005); 및 Babitskai, VG et al., Prikladmaya Bioxhimiya Mikrobiologiya, 36:439 (2000)) 등의 연구가 진행되었으며, 특히 항당뇨연구로는 차가버섯 추출 정제물이 세포주기 조절 효소인 cdc25와 cdc2/cyclin B를 강력히 억제하므로 혈당강하 효과를 나타낸다는 것이 보고되었다 (Mizuno T et al., Int. J. Med. Mushroom 1:301 (1999)).Studies on the physiological activity of chaga mushrooms include antitumor (Bultov PK et al., Tsaga ii ee letsebnoje primenie pirake IV. Stadii Leningrad 326 (1959); Shivrina AN, Chem Abstr . 66: 17271-17279 (1967); Loviagina EV et al., Biobimija 27: 794-800 (1962); and Kahlos K. et al., Acta Pharm Fenn 96: 33-40 (1987)), antimutation (Saitoh et al., 46tum (1996)), antiviral (Kahlos K et al., Fitoterapia 57: 4 (1996); and Ichmura T et al., Biosci. Biotechnol. Biochem . 62: 575 (1998)), and antioxidant (Cui Y et al., J. Ethnopharmacol. 96 (1-2): 79 (2005); and Babitskai, VG et al., Prikladmaya Bioxhimiya Mikrobiologiya , 36: 439 (2000)). It has been reported that chaga extract extract exhibits a hypoglycemic effect by strongly inhibiting the cell cycle regulating enzymes cdc25 and cdc2 / cyclin B (Mizuno T et al., Int. J. Med. Mushroom 1: 301 ( 1999).
이에, 본 발명자들은 홍미삼 추출물, 차가버섯 추출물 및 홍미삼과 차가버섯의 혼합 추출물 등에 대한 혈당강하 효과 비교 실험을 실시한 결과, 홍미삼이 홍삼이나 미삼보다 우수한 혈당강하 작용을 나타내며, 특히 홍미삼과 차가버섯의 혼합 추출물이 홍미삼 추출물 또는 차가버섯 추출물을 단독으로 사용했을 때보다 현저히 우수한 혈당강하 작용을 나타내는 것을 발견함으로써 본 발명을 완성하게 되었다.Therefore, the present inventors conducted a blood sugar lowering effect comparison experiment on the red ginseng extract, chaga mushroom extract and the mixed extract of red and red ginseng and chaga mushroom, red ginseng showed better blood sugar lowering effect than red ginseng or misam, in particular, the mixture of red ginseng and chaga The present invention has been completed by discovering that the extract exhibits a significantly lower blood sugar lowering effect than when the red ginseng extract or chaga extract is used alone.
본 발명의 목적은 홍미삼 추출물 또는 홍미삼과 차가버섯을 혼합하여 추출한 혼합 추출물을 활성성분으로 함유하는, 당뇨병을 예방 및 치료하기 위한 약학 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for preventing and treating diabetes, which contains red ginseng extract or a mixed extract extracted by mixing red ginseng and chaga mushroom as an active ingredient.
또한, 본 발명의 목적은 상기 추출물을 활성성분으로 함유하는, 혈당량을 강하시키기 위한 식품을 제공하는 것이다. It is also an object of the present invention to provide a food for lowering blood sugar, which contains the extract as an active ingredient.
상기 목적에 따라, 본 발명에서는 활성성분으로서 홍미삼 추출물 또는 홍미삼과 차가버섯의 혼합 추출물을 약학적으로 허용가능한 담체와 함께 함유하는, 당뇨병의 예방 및 치료용 약학 조성물을 제공한다.In accordance with the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of diabetes, containing red ginseng extract or a mixed extract of red ginseng and chaga mushroom as an active ingredient with a pharmaceutically acceptable carrier.
또한, 본 발명에서는 활성성분으로서 홍미삼 추출물 또는 홍미삼과 차가버섯의 혼합 추출물을 함유하는, 혈당량을 강하시키기 위한 식품을 제공한다. In addition, the present invention provides a food for lowering blood glucose levels, which contains red ginseng extract or a mixed extract of red ginseng and chaga as an active ingredient.
이하, 본 발명에 대하여 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에 사용되는 홍미삼 추출물은, 완전히 건조된 홍미삼을 파쇄한 후, 증류수로 80 내지 100℃에서 3 내지 6 시간 동안 수회 추출한 다음, 얻어진 추출액을 여과하고 감압 농축함으로써 얻을 수 있다.The red ginseng extract used in the present invention can be obtained by crushing completely dried red ginseng, extracted several times with distilled water at 80 to 100 ° C. for 3 to 6 hours, and then filtering the obtained extract and concentrating under reduced pressure.
구체적으로, 본 발명의 바람직한 실시예에서는 완전 건조 홍미삼을 파쇄한 후 증류수로 100℃에서 5 시간 동안 3 회 추출한 후, 얻어진 추출액을 여과하고 감압 농축시켜 홍미삼 추출물을 얻는다.Specifically, in the preferred embodiment of the present invention, after completely crushed dried red ginseng and extracted three times for 5 hours at 100 ℃ with distilled water, the obtained extract is filtered and concentrated under reduced pressure to obtain a red rice ginseng extract.
또한, 본 발명에 사용되는 홍미삼과 차가버섯의 혼합 추출물은, 완전히 건조된 홍미삼 및 차가버섯을 1 내지 10 : 1의 중량비, 바람직하게는 1 내지 5 : 1의 중량비로 혼합한 후, 증류수로 80 내지 100℃에서 3 내지 6 시간 동안 수회 추출한 다음, 얻어진 추출액을 여과하고 감압 농축함으로써 얻을 수 있다.In addition, the mixed extract of red ginseng and chaga mushroom used in the present invention, after mixing completely dried red ginseng and chaga mushroom in a weight ratio of 1 to 10: 1, preferably 1 to 5: 1, and then distilled water 80 After extraction several times for 3 to 6 hours at -100 ℃, it can be obtained by filtration and concentration under reduced pressure.
구체적으로, 본 발명의 바람직한 실시예에서는 홍미삼과 차가버섯을 각각 1 내지 5 : 1의 중량비로 혼합한 것을 증류수로 100℃에서 5 시간 동안 3 회 추출한 후, 얻어진 추출액을 여과하고 감압 농축시켜 홍미삼과 차가버섯의 혼합 추출물을 얻는다.Specifically, in a preferred embodiment of the present invention, the mixture of red ginseng and chaga mushroom was mixed at a weight ratio of 1 to 5: 1, respectively, three times with distilled water at 100 ° C. for 5 hours, and the obtained extract was filtered and concentrated under reduced pressure. Obtain a mixed extract of chaga.
본 발명의 홍미삼 추출물은 기존의 미삼 또는 홍삼 추출물보다 우수한 혈당강하 효과를 나타내므로 당뇨를 예방 및 치료하는데 유용하게 사용될 수 있다.The red ginseng extract of the present invention exhibits an excellent hypoglycemic effect than the conventional ginseng or red ginseng extract and thus may be usefully used for preventing and treating diabetes.
또한, 상기 홍미삼과 차가버섯의 혼합 추출물은 두 활성성분의 혼합으로 인한 상가작용으로 홍미삼 또는 차가버섯을 단독으로 사용한 추출물 보다 우수한 혈당강하 효과를 나타내므로, 당뇨를 예방 및 치료하는데 유용하게 사용될 수 있다.In addition, the mixed extract of the red ginseng and chaga mushroom has a superior hypoglycemic effect than the extract using the red ginseng or chaga mushroom alone due to the additive action of the two active ingredients, it can be useful for preventing and treating diabetes. .
본 발명의 홍미삼 추출물 또는 홍미삼과 차가버섯의 혼합 추출물은 통상적인 방법에 따라 약제학적으로 허용되는 적절한 담체 또는 부형제와 혼합하거나 희석제로 희석하여 상기한 기능을 갖는 약학 조성물을 제조할 수 있다. 적합한 담체, 부형제 및 희석제의 예로는, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알긴산, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 미정질 셀룰로스, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 상기 약학 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 포함할 수 있다. 본 발명의 약학 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있다. 제형은 정제, 알약, 분말, 새세이 (sachet), 엘릭시르 (elixir), 현탁액, 에멀젼, 용액, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 멸균 주사용액, 멸균 분말 등의 형태일 수 있다. The red ginseng extract of the present invention or the mixed extract of red ginseng and chaga mushroom may be mixed with a suitable pharmaceutically acceptable carrier or excipient or diluted with a diluent according to a conventional method to prepare a pharmaceutical composition having the above functions. Examples of suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginic acid, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The pharmaceutical composition may further include fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like. The pharmaceutical compositions of the invention may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. The formulations may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders and the like.
본 발명의 약학 조성물은 경구, 경피, 피하, 정맥 또는 근육을 포함한 여러 경로를 통해 투여될 수 있다. 본 발명의 활성성분의 통상적인 1일 투여량은 홍미삼 추출물의 경우, 10 내지 100 ㎎/㎏ 체중, 바람직하게는 30 내지 50 ㎎/㎏ 체중의 범위이고, 홍미삼과 차가버섯의 혼합추출물의 경우, 10 내지 100 ㎎/㎏ 체중, 바람직하게는 30 내지 50 ㎎/㎏ 체중의 범위이며, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 활성성분의 실제 투여량은 투여 경로, 환자의 연령, 성별 및 체중, 및 질환의 중증도 등의 여러 관련 인자에 비추어 결정되어야 하는 것으로 이해되어야 하며, 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The pharmaceutical compositions of the invention can be administered via several routes including oral, transdermal, subcutaneous, intravenous or intramuscular. A typical daily dosage of the active ingredient of the present invention ranges from 10 to 100 mg / kg body weight, preferably from 30 to 50 mg / kg body weight for red ginseng extract, and for the mixed extract of red ginseng and chaga, It is in the range of 10 to 100 mg / kg body weight, preferably 30 to 50 mg / kg body weight, and can be administered once or divided into several doses. However, it should be understood that the actual dosage of the active ingredient should be determined in light of several relevant factors such as the route of administration, the age, sex and weight of the patient, and the severity of the disease, and therefore, the dosage may be determined in any respect to the invention It does not limit the scope of.
또한, 본 발명에서는 유효량의 홍미삼 추출물 또는 홍미삼과 차가버섯의 혼합 추출물을 함유하는, 혈당강하를 위한 식품을 제공한다. 상기 효과를 나타내기 위하여 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들면 각종 식품류, 육류, 음료수, 초콜렛, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 알코올 음료, 비타민 복합제 및 그 밖의 건강보조식품류 등이 있으나, 이에 한정되는 것은 아니다. In addition, the present invention provides a food for hypoglycemic, containing an effective amount of red ginseng extract or a mixed extract of red ginseng and chaga mushroom. Foods to which the extract of the present invention may be added to exhibit the above effects include, for example, various foods, meat, beverages, chocolate, snacks, confectionery, pizza, ramen, other noodles, gums, ice creams, alcoholic beverages, Vitamin complexes and other health supplements, but are not limited thereto.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited by the following examples.
실시예 1Example 1 : 홍미삼 추출물의 제조: Preparation of Red Ginseng Extract
금산에서 제조된 완전 건조 홍미삼 300 g을 파쇄한 후, 증류수 3 ℓ로 100℃에서 5 시간 동안 3 회 추출한 후, 얻어진 추출물을 여과하고 감압 농축시켜 홍미삼 추출물 48 g (수율: 16%)을 제조하였다.After crushing 300 g of completely dried red ginseng prepared in Geumsan, and extracting three times for 5 hours at 100 ° C. with 3 L of distilled water, the obtained extract was filtered and concentrated under reduced pressure to prepare 48 g (yield: 16%) of red ginseng extract. .
실시예 2Example 2 : 홍미삼과 차가버섯의 혼합 추출물의 제조: Preparation of Mixed Extract of Red Ginseng and Chaga
(2-1) 1 : 1 혼합 추출물의 제조(2-1) Preparation of 1: 1 Mixture Extract
홍미삼과 차가버섯을 각각 300 g씩 평량하여 혼합한 다음, 증류수 5 ℓ를 넣고 100℃에서 5 시간 동안 3 회 추출한 후, 얻어진 추출액을 여과하고 감압 농축시켜 홍미삼과 차가버섯의 1 : 1 혼합 추출물 122 g (수율: 20%)을 제조하였다.300 g each of red ginseng and chaga were weighed and mixed. Then, 5 L of distilled water was added and extracted three times at 100 ° C. for 5 hours. The obtained extract was filtered and concentrated under a reduced pressure to obtain 1: 1 mixed extract of red ginseng and chaga. g (yield: 20%) was prepared.
(2-2) 2 : 1 혼합 추출물의 제조(2-2) Preparation of 2: 1 Mixed Extract
홍미삼과 차가버섯을 각각 600 g과 300 g씩 평량하여 혼합한 것을 제외하고는 상기 (2-1)과 동일한 방법으로 홍미삼과 차가버섯의 2 : 1 혼합 추출물 175 g (수율: 19%)을 제조하였다.175 g (yield: 19%) of 2: 1 mixed extract of red ginseng and chaga was prepared in the same manner as in (2-1), except that red ginseng and chaga were weighed by 600 g and 300 g, respectively. It was.
(2-3) 3 : 1 혼합 추출물의 제조(2-3) Preparation of 3: 1 Mixed Extract
홍미삼과 차가버섯을 각각 900 g과 300 g씩 평량하여 혼합한 것을 제외하고는 상기 (2-1)과 동일한 방법으로 홍미삼과 차가버섯의 3 : 1 혼합 추출물 225 g ( 수율: 19%)을 제조하였다.225 g (yield: 19%) of 3: 1 mixed extract of red ginseng and chaga was prepared in the same manner as in (2-1), except that 900 g and 300 g of red ginseng and chaga were weighed in the same basis. It was.
(2-4) 4 : 1 혼합 추출물의 제조(2-4) Preparation of 4: 1 Mixed Extract
홍미삼과 차가버섯을 각각 1,200 g과 300 g씩 평량하여 혼합한 것을 제외하고는 상기 (2-1)과 동일한 방법으로 홍미삼과 차가버섯의 4 : 1 혼합 추출물 315 g (수율: 21%)을 제조하였다.315 g (yield: 21%) of a 4: 1 mixed extract of red ginseng and chaga was prepared in the same manner as in (2-1), except that red ginseng and chaga were weighed by 1,200 g and 300 g, respectively. It was.
(2-5) 5 : 1 혼합 추출물의 제조(2-5) Preparation of 5: 1 Mixed Extract
홍미삼과 차가버섯을 각각 1,500 g과 300 g씩 평량하여 혼합한 것을 제외하고는 상기 (2-1)과 동일한 방법으로 홍미삼과 차가버섯의 5 : 1 혼합 추출물 402 g (수율: 22%)을 제조하였다.402 g (yield: 22%) of a 5: 1 mixed extract of red ginseng and chaga was prepared in the same manner as in (2-1), except that 1,500 g and 300 g of red ginseng and chaga were mixed in the basis weight. It was.
실시예 3Example 3 : 홍삼 추출물, 미삼 추출물 및 차가버섯 추출물의 제조 : Preparation of Red Ginseng Extract, Misam Extract and Chaga Extract
홍삼 300 g, 미삼 300 g 및 차가버섯 300 g을 각각 사용한 것을 제외하고는 실시예 2의 (2-1)과 동일한 방법으로 홍삼 추출물 62 g, 미삼 추출물 68 g 및 차가버섯 추출물 112 g을 각각 제조하였다. Red ginseng extract 62 g, rice ginseng extract 68 g and chaga mushroom extract 112 g were prepared in the same manner as in Example 2 (2-1), except that 300 g red ginseng, 300 g ginseng and 300 g chaga were used. It was.
시험예 1Test Example 1 : 홍미삼 추출물, 차가버섯 추출물 및 홍미삼과 차가버섯의 혼합 추출물의 단회 투여 독성시험: Single dose toxicity test of red ginseng extract, chaga extract and mixed extract of red ginseng and chaga
상기 실시예 1에서 제조된 홍미삼 추출물, 실시예 2에서 제조된 홍미삼과 차 가버섯의 혼합 추출물 및 실시예 3에서 제조된 차가버섯 추출물 각각을, 실험하기 전날 저녁부터 16 시간 동안 절식시킨 ICR계 마우스 수컷 (체중: 23±2 g) 10 마리씩에 각각 경구 투여 및 비경구 투여 (복강주사)한 다음, 각 군의 마우스들의 행동 이상 유무를 관찰하고 72 시간 후의 사망률을 측정하여 리치필드 제이티 및 윌콕슨 에프의 방법에 따라 LD50값을 계산하고, 그 결과를 하기 표 1에 나타내었다.ICR-based mice fasted for 16 hours from the evening before the experiment, each of the red ginseng extract prepared in Example 1, the mixed extract of red ginseng and chaga mushroom prepared in Example 2 and chaga extract prepared in Example 3 Each male (weight: 23 ± 2 g) was administered orally and parenterally (intraperitoneally), respectively, and then observed behavioral abnormalities in the mice of each group, and the mortality was measured 72 hours later by Richfield Jetty and Wilcoxon. LD 50 value was calculated according to F's method, and the results are shown in Table 1 below.
상기 표 1에 나타난 바와 같이, 홍미삼 추출물, 홍미삼과 차가버섯의 혼합 추출물 및 차가버섯 추출물은 모든 실험군에서 매우 높은 안전성을 나타내었다.As shown in Table 1, the red ginseng extract, the mixed extract of red ginseng and chaga and chaga extract showed very high safety in all experimental groups.
시험예 2Test Example 2 : 홍미삼 추출물과 홍삼 추출물의 혈당강하 효과 시험: Hypoglycemic Effect Test of Red Ginseng Extract and Red Ginseng Extract
실험하기 전 16 시간 동안 절식시킨 ICR계 마우스 수컷 (체중: 25±2 g)을 10 마리씩 나누어 알록산 75 ㎎/㎏을 정맥 내 투여하고 48 내지 72 시간 후 채혈하여 혈당치가 400 ㎎/㎗ 이상인 것을 당뇨쥐로 선택하여 실험에 사용하였으며, 상기 실시예 1에서 제조된 홍미삼 추출물과 실시예 3에서 제조된 홍삼 추출물을 동일 용량이 되도록 생리 식염수에 녹여 5 일 동안 정해진 시간마다 용량별로 경구 투여하였고, 투여 120 분 후 꼬리 미정맥으로부터 채혈하여 글루코오스 옥시다아제법에 의해 혈당을 측정함으로써 5 일간의 혈당강하 추이를 관찰하였으며, 그 결과를 하기 표 2에 나타내었다.ICR-based male males (weight: 25 ± 2 g) fasted for 16 hours before the experiment were divided into 10 doses of 75 mg / kg of alloxane intravenously and collected after 48 to 72 hours, and the blood glucose level was 400 mg / dl or more. Diabetic rats were used for the experiment, and the red ginseng extract prepared in Example 1 and the red ginseng extract prepared in Example 3 were dissolved in physiological saline so as to have the same dose, and orally administered by dose every 5 days. After 120 minutes, blood was collected from the tail vein and blood glucose was measured by glucose oxidase method to observe the hypoglycemic trend for 5 days, and the results are shown in Table 2 below.
상기 표 2에 나타난 바와 같이, 홍미삼 추출물은 홍삼 추출물 보다 약 28% 정도 더 우수한 혈당강하 효과를 나타내었다. As shown in Table 2, the red ginseng extract showed about 28% better hypoglycemic effect than the red ginseng extract.
시험예 3Test Example 3 : 홍미삼 추출물과 미삼 추출물의 혈당강하 효과 시험: Hypoglycemic Effect Test of Red Ginseng Extract and Misam Extract
홍삼 추출물 대신에 실시예 3에서 제조된 미삼 추출물을 사용한 것을 제외하고는 상기 시험예 2와 동일한 방법으로 홍미삼 추출물과 미삼 추출물의 혈당강하 추이를 관찰하였으며, 그 결과를 하기 표 3에 나타내었다.Except for using the ginseng extract prepared in Example 3 instead of the red ginseng extract was observed the hypoglycemic trend of the red ginseng extract and the extract of the ginseng extract in the same manner as in Test Example 2, the results are shown in Table 3.
상기 표 3에 나타난 바와 같이, 홍미삼 추출물이 미삼 추출물보다 약 43% 정도 더 우수한 혈당강하 효과를 나타내었다.As shown in Table 3, the red ginseng extract showed about 43% better hypoglycemic effect than the extract.
따라서, 본 발명의 홍미삼 추출물은 동일 용량의 홍삼 또는 미삼 추출물보다 혈당강하 효과가 우수함을 알 수 있다.Therefore, it can be seen that the red ginseng extract of the present invention has an excellent hypoglycemic effect than the same dose of red ginseng or misam extract.
시험예 4Test Example 4 : 홍미삼 추출물의 혈당강하 효과 시험: Blood Glucose Lowering Effect Test of Red Ginseng Extract
홍미삼 추출물을 생리 식염수에 녹여 4 일 동안 정해진 시간 마다 500 및 1,000 ㎎/㎏의 용량으로 경구 투여한 것을 제외하고는 상기 시험예 2와 동일한 방법으로 혈당강하 효과의 추이를 관찰하였으며, 그 결과를 하기 표 4에 나타내었다.The trend of hypoglycemic effect was observed in the same manner as in Test Example 2, except that red ginseng extract was dissolved in physiological saline and orally administered at a dose of 500 and 1,000 mg / kg every 4 days. Table 4 shows.
상기 표 4에 나타난 바와 같이, 홍미삼 추출물은 500 및 1,000 ㎎/㎏ 투여군에서 각각 40.6%와 57.5%의 용량 의존적 혈당강하 효과를 나타내었다.As shown in Table 4, red ginseng extract showed a dose-dependent hypoglycemic effect of 40.6% and 57.5% in the 500 and 1,000 mg / kg administration group, respectively.
시험예 5Test Example 5 : 홍미삼 추출물, 차가버섯 추출물 및 홍미삼과 차가버섯의 혼합 추출물의 혈당강하 효과 비교 시험: Comparison of Hypoglycemic Effects of Red Ginseng Extract, Chaga Extract, and Mixed Extract of Red Ginseng and Chaga
추출물로서 실시예 1에서 제조된 홍미삼 추출물, 실시예 2의 (2-1) 내지 (2-5)에서 제조된 홍미삼과 차가버섯의 혼합 추출물 및 실시예 3에서 제조된 차가버섯 추출물을 사용한 것을 제외하고는 시험예 2와 동일한 방법으로 혈당강하 효과의 추이를 관찰하였으며, 그 결과를 하기 표 5에 나타내었다.Except for using the red ginseng extract prepared in Example 1, the mixed extract of red ginseng and chaga mushrooms prepared in (2-1) to (2-5) of Example 2 and the chaga mushroom extract prepared in Example 3 as an extract And the trend of hypoglycemic effect was observed in the same manner as in Test Example 2, the results are shown in Table 5 below.
상기 표 5에 나타난 바와 같이, 홍미삼과 차가버섯의 1 : 1 혼합 추출물은 동일 용량의 홍미삼 추출물이나 차가버섯의 단독 추출물보다 우수한 혈당강하 효과를 나타내었고, 혼합 추출물에서 홍미삼의 함량이 증가할수록 효과는 증대되어, 홍미삼과 차가버섯의 혼합비가 4 : 1일 때 약 46% 정도 더 우수한 혈당강하 효과를 나타내었다. 따라서, 홍미삼과 차가버섯이 혼합 추출되면서 두 가지 활성성분 상호간의 상가작용으로 보다 우수한 항당뇨 효과를 나타냄을 알 수 있다.As shown in Table 5, the 1: 1 mixed extract of red ginseng and chaga mushroom showed a better hypoglycemic effect than the single dose of red ginseng extract or chaga mushroom of the same dose, and the effect was increased as the content of red ginseng increased in the mixed extract. Increasingly, when the mixing ratio of red ginseng and chaga was 4: 1, the blood sugar lowering effect was about 46%. Therefore, it can be seen that the red ginseng and chaga mushrooms are mixed and extracted to show an excellent anti-diabetic effect by the additive action between the two active ingredients.
시험예 6Test Example 6 : 홍미삼과 차가버섯의 4 : 1 혼합 추출물의 혈당강하 효과 시험: Hypoglycemic Effect Test of 4: 1 Mixed Extract of Red Ginseng and Chaga
추출물로서 실시예 2의 (2-4)에서 제조된 홍미삼과 차가버섯의 4 : 1 혼합 추출물을 125, 250 및 500 ㎎/㎏의 용량으로 사용한 것을 제외하고는 시험예 2와 동일한 방법으로 혈당강하 효과의 추이를 관찰하였으며, 그 결과를 하기 표 6에 나타내었다.Except for using the 4: 1 mixed extract of red ginseng and chaga mushroom prepared in Example 2 (2-4) as the extract at doses of 125, 250 and 500 mg / kg, the blood sugar drop was performed in the same manner as in Test Example 2. The transition of the effect was observed and the results are shown in Table 6 below.
상기 표 6에 나타난 바와 같이, 홍미삼과 차가버섯의 4 : 1 혼합 추출물은 125, 250 및 500 ㎎/㎏ 투여군에서 각각 27.6, 38.5 및 48.1%의 용량 의존적으로 유의성있는 혈당강하 효과를 나타내었다.As shown in Table 6, the 4: 1 mixed extract of red ginseng and chaga mushroom showed dose-dependently significant hypoglycemic effects of 27.6, 38.5 and 48.1% in 125, 250 and 500 mg / kg administration groups, respectively.
상기에서 살펴본 바와 같이, 홍미삼 추출물은 홍삼 또는 미삼 추출물 보다 우수한 혈당강하 효과를 나타내며, 특히 홍미삼과 차가버섯의 혼합 추출물은 홍미삼과 차가버섯이 혼합 추출되면서 두 가지 활성성분 상호간의 상가작용으로 홍미삼 또는 차가버섯의 단독 추출물보다 우수한 혈당강하 효과를 나타내므로, 본 발명에서 사용된 홍미삼 추출물 또는 홍미삼과 차가버섯의 혼합 추출물은 당뇨병을 예방 또는 치료하기 위한 약학 조성물 및 혈당량을 강하시키기 위한 다양한 식품에 유용하게 사용될 수 있다.As described above, the red ginseng extract exhibits a better hypoglycemic effect than the red ginseng or the ginseng extract, in particular, the mixed extract of the red ginseng and chaga mushroom is the red and red ginseng or chaga as the additive activity between the two active ingredients Since it exhibits an excellent hypoglycemic effect than the extract of the mushroom alone, the red ginseng extract or the mixed extract of red ginseng and chaga mushroom used in the present invention may be usefully used in pharmaceutical compositions for preventing or treating diabetes and various foods for lowering blood glucose levels. Can be.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050119784A KR100740413B1 (en) | 2005-12-08 | 2005-12-08 | Composition for preventing and treating diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050119784A KR100740413B1 (en) | 2005-12-08 | 2005-12-08 | Composition for preventing and treating diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070060420A true KR20070060420A (en) | 2007-06-13 |
KR100740413B1 KR100740413B1 (en) | 2007-07-16 |
Family
ID=38356445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050119784A KR100740413B1 (en) | 2005-12-08 | 2005-12-08 | Composition for preventing and treating diabetes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100740413B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107136262A (en) * | 2017-05-19 | 2017-09-08 | 马永辉 | One seed ginseng stilbene tea and its processing technology |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH119223A (en) * | 1997-06-26 | 1999-01-19 | Kyowa Eng Kk | Healthy food |
-
2005
- 2005-12-08 KR KR1020050119784A patent/KR100740413B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107136262A (en) * | 2017-05-19 | 2017-09-08 | 马永辉 | One seed ginseng stilbene tea and its processing technology |
Also Published As
Publication number | Publication date |
---|---|
KR100740413B1 (en) | 2007-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100864455B1 (en) | A Composition comprising the extract of complex herb improving Liver Cirrhosis, cytotoxicity and liver injury for preventing and treating of liver disease | |
KR101613693B1 (en) | Composition for Prevention or Treatment of Skin Disease Comprising an Extract of Sargassum Horneri and Method of Preparing The Same | |
KR101328668B1 (en) | Compositon with anti-obesity and anti-diabetic activity comprising cudrania tricuspidata and adlay, and use thereof | |
KR101341693B1 (en) | Composition comprising the extract of herbs for preventing or treating neurodegenerative disorders | |
KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
KR20140034620A (en) | Composition for preventing or treating diabetbes mellitus disease containing extract of plants | |
KR100949482B1 (en) | Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
EP2567704A1 (en) | Traditional chinese medicine composition for treating diabetes and preparation method thereof | |
KR100740413B1 (en) | Composition for preventing and treating diabetes | |
KR100964603B1 (en) | Phamaceutical composition of diabetes mellitus using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
KR102538751B1 (en) | Pharmaceutical composition and food composition for treating erectile dysfunction | |
KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
KR20190062833A (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
KR100569089B1 (en) | Composition having brain function and congnition enhancing activity | |
KR20120092444A (en) | A composition comprising s for cerebral apoplexy, hypertension, arteriosclerosis and hyperlipidemia, and method for preparation thereof | |
KR20060015055A (en) | Composition comprising the crude extract of the hydrangea serrata seringe var. thumbergii sugimoto for lowering blood glucose and hyperlipidemia | |
KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
KR100750873B1 (en) | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease | |
KR102662439B1 (en) | A composition comprising Fomitopsis pinicola for preventing or treating diabetes mellitus | |
KR102172371B1 (en) | A pharmaceutical composition comprising extract of Aloe, quince and corn silk for preventing or treating obesity | |
KR101278706B1 (en) | Compositions and functional food for prevention or treatment of diabetic complications comprising using extract of Hedera rhombea | |
CA2708901A1 (en) | A composition for treating hyperglycemia and a process thereof | |
CA3020774C (en) | Uses of poria cocos extract and tumulosic acid in protecting muscles | |
KR20100042139A (en) | The composition comprising enzyme-treated extracts of momordica charantia l. for the prevention and treatment of diabetic complications | |
KR100758267B1 (en) | Compositions effective for removing hangover, which contain natural plant extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20110708 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |